Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study

Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish comparability of a high-productivity, suspension-based PBFT02 manufacturing process

Read more at globenewswire.com